Lido Advisors’s ARK Genomic Revolution ETF ARKG Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q2
Sell
-6,887
Closed -$207K 1218
2023
Q1
$207K Buy
6,887
+120
+2% +$3.72K ﹤0.01% 1003
2022
Q4
$191K Sell
6,767
-122,655
-95% -$3.89M ﹤0.01% 902
2022
Q3
$4.25M Sell
129,422
-27,799
-18% -$1.02M 0.05% 162
2022
Q2
$4.95M Sell
157,221
-3,190
-2% -$112K 0.07% 136
2022
Q1
$7.37M Buy
160,411
+41,056
+34% +$1.96M 0.08% 115
2021
Q4
$7.42M Buy
119,355
+20,689
+21% +$1.43M 0.08% 127
2021
Q3
$7.37M Buy
98,666
+13,387
+16% +$1.12M 0.1% 108
2021
Q2
$7.89M Buy
85,279
+32,763
+62% +$2.79M 0.11% 109
2021
Q1
$4.66M Buy
52,516
+11,375
+28% +$1.13M 0.08% 142
2020
Q4
$3.84M Buy
41,141
+18,581
+82% +$1.48M 0.08% 141
2020
Q3
$1.44M Buy
22,560
+9,036
+67% +$529K 0.04% 204
2020
Q2
$705K Buy
13,524
+1,353
+11% +$58K 0.02% 292
2020
Q1
$381K Buy
12,171
+6,163
+103% +$206K 0.02% 381
2019
Q4
$201K Buy
+6,008
New +$191K 0.01% 619

Other funds holding ARKG

Lido Advisors's ARKG Position: Q2 2023 in Review

Lido Advisors sold out of ARK Genomic Revolution ETF (ARKG) in Q2 2023, closing a stake of 6,887 shares — an estimated $207K sold.

Lido Advisors first reported a position in ARKG in Q4 2019 and held it in 14 quarters. The position peaked at $7.89M in Q2 2021. 290 funds tracked by Wall St. Rank hold ARKG as of Q2 2023.

  • Lido Advisors reported no remaining ARK Genomic Revolution ETF position as of Q2 2023 after selling out during the quarter.
  • Lido Advisors sold 6,887 ARK Genomic Revolution ETF shares in Q2 2023, an estimated $207K.
  • Lido Advisors first reported a position in ARK Genomic Revolution ETF in Q4 2019 and held it in 14 quarters.
  • Lido Advisors's ARK Genomic Revolution ETF position peaked at $7.89M in Q2 2021.
  • 290 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q2 2023.

Based on Lido Advisors's 13F filing for Q2 2023, filed 9 Aug 2023.